PMID: 9175621Mar 1, 1997Paper
Identification of pore-forming subunit of P-type calcium channels: an antisense study on rat cerebellar Purkinje cells in culture
Neuropharmacology
S GillardD Lodge
Abstract
Treatment of cerebellar neurones in culture with an antisense oligonucleotide (ODN) against alpha1A, reduced the whole-cell P-type calcium channel current relative to mismatch ODN treated controls (p < 0.001). Therefore, AgaIVA (50 nM) reduced whole-cell calcium current in mismatch and antisense treated cells by 70 +/- 4 and 19 +/- 3%, respectively.
References
Feb 27, 1992·Nature·I M MintzM E Adams
Jul 17, 1992·Science·M E WilliamsM M Harpold
Jul 1, 1991·Neuron·T P SnutchM M Gilbert
Oct 1, 1994·Cellular and Molecular Neurobiology·K H SchlingensiepenW Brysch
Jan 1, 1994·Annual Review of Neuroscience·F HofmannV Flockerzi
Aug 1, 1993·Neuron·W A SatherR W Tsien
Sep 1, 1997·Neuroscience·S G VolsenM M Harpold
❮ Previous
Next ❯
Citations
Nov 17, 2004·Neurotoxicity Research·Francis C LauLouise C Abbott
Sep 17, 2010·The Cerebellum·Saak V Ovsepian, David D Friel
Feb 14, 2002·Progress in Biophysics and Molecular Biology·T E Fisher, C W Bourque
Nov 14, 1997·Trends in Pharmacological Sciences·J M NooneyA Feltz
Apr 25, 2003·Neuroscience·T C FrankL C Abbott
Jul 17, 1999·Neuroscience·M SchrammT Schneider
Aug 7, 2002·British Journal of Pharmacology·F GiovanniniB Lang
Aug 24, 1999·The European Journal of Neuroscience·P J CraigS G Volsen
Jan 5, 1999·The Journal of General Physiology·K MellitiB Adams
Apr 4, 2002·The Journal of General Physiology·Stefan I McDonoughBruce P Bean
Jan 1, 1997·Epilepsia·B S Meldrum
Jul 22, 1999·Annals of the New York Academy of Sciences·A C DolphinC Cantí
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·E S Piedras-RenteríaP M Best
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·K JunH S Shin
Jun 24, 1998·Proceedings of the National Academy of Sciences of the United States of America·E S Piedras-Rentería, R W Tsien
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·A PintoJ Boot
Apr 6, 2006·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Kylie A ScogganDennis E Bulman
Nov 26, 2003·Experimental Neurology·Kathryn A Whyte, Susan A Greenfield
Apr 18, 2002·Journal of Neuroimmunology·Samantha E GillardRichard J Miller
Jul 8, 2000·Neuropharmacology·R M LeãoP S Beirão
Nov 25, 2006·The Journal of Physiology·Elizabeth W TringhamMaria M Usowicz
Oct 1, 2008·Neuropharmacology·Lisa M SmythVioleta N Mutafova-Yambolieva
Mar 6, 1999·The Journal of Physiology·N L Brice, A C Dolphin
Apr 23, 2005·The European Journal of Neuroscience·M A KampT Schneider
Nov 13, 2013·The Journal of Physiology·Tomohiko IrieHirokazu Hirai
Nov 16, 2007·The European Journal of Neuroscience·Kathryn S RichardsKurt Bommert
Jun 23, 2011·PloS One·Andrew J Giessel, Bernardo L Sabatini
Jan 5, 2002·The Journal of Biological Chemistry·Taiji TsunemiTsutomu Tanabe
Jul 19, 2000·Journal of Neurophysiology·L S DoveW H Griffith
Jul 22, 1999·Annals of the New York Academy of Sciences·S M SmithR W Tsien
Jul 22, 1999·Annals of the New York Academy of Sciences·H Moreno Davila
❮ Previous
Next ❯
Related Concepts
Related Feeds
Antisense Oligonucleotides: ND
This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.
Related Papers
Proceedings of the National Academy of Sciences of the United States of America
H MorenoR Llinás
The European Journal of Neuroscience
N S BerrowA C Dolphin
European Journal of Pharmacology
A JørgensenM Treiman
Bioorganic & Medicinal Chemistry
Sara CesariniRoberta Loddo